Chemotherapy: Greater potential benefit in overall survival for eribulin compared with capecitabine

Chemotherapy: Greater potential benefit in overall survival for eribulin compared with capecitabine:

Subgroup analyses from a phase III clinical trial comparing a newer chemotherapy agent called eribulin mesylate, with capecitabine, a standard chemotherapy medication in women with previously treated metastatic breast cancer, showed increased benefit among women sharing certain traits. Specifically, these analyses demonstrated a greater potential benefit in certain subsets of patients with metastatic breast cancer.
Fuente : http://feeds.sciencedaily.com/~r/sciencedaily/~3/E...

Tendencias 21 (Madrid). ISSN 2174-6850